| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0338 |
| Trial ID | NCT02935257 |
| Disease | Small Lymphocytic Lymphoma | B-Cell Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AUTO1|Obecabtagene autoleucel|obe-cel |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19) |
| Year | 2017 |
| Country | United Kingdom |
| Company sponsor | University College, London |
| Other ID(s) | UCL/16/0530 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||